BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-02 |
2024-03 |
-0.4 |
-0.05 |
0.35 |
87.50% |
2024-02-22 |
2023-12 |
-0.95 |
-0.96 |
-0.01 |
-1.05% |
2024-02-22 |
2023-12 |
-0.95 |
N/A |
N/A |
N/A |
2023-11-02 |
2023-09 |
-0.86 |
N/A |
N/A |
N/A |
2023-11-02 |
2023-09 |
-0.86 |
-1.08 |
-0.22 |
-25.58% |
2023-08-03 |
2023-06 |
-0.86 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-27 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-08-16 |
JP Morgan |
Upgrade |
Overweight |
Overweight |
2023-08-13 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-07-17 |
Goldman Sachs |
Upgrade |
Buy |
Buy |
2023-07-17 |
Raymond James |
Upgrade |
Outperform |
Outperform |
2023-07-17 |
Jefferies |
Downgrade |
Buy |
Hold |
Date |
Name |
Relation |
Quantity |
Description |
2022-03-13 |
DACHILLE DOUGLAS A. |
Director |
0.00 |
Purchase |
2022-03-14 |
ELLIS ANDREA |
Director |
12.00K |
Purchase |
2024-02-15 |
HOMCY CHARLES J |
Director |
1.23M |
Conversion of Exercise of derivative security |
2024-02-15 |
KUMAR NEIL |
Chief Executive Officer |
6.88M |
Conversion of Exercise of derivative security |
2023-12-25 |
MCCORMICK FRANK |
Director |
0.00 |
Sale |
2023-02-15 |
SCHELLER RICHARD H |
Director |
53.82K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Kohlberg Kravis Roberts & Co. L.P. |
31.06M |
534.25M |
19.12% |
2023-06-29 |
Viking Global Investors, L.P. |
26.62M |
457.88M |
16.38% |
2023-06-29 |
Vanguard Group Inc |
11.68M |
200.98M |
7.19% |
2023-06-29 |
Blackrock Inc. |
9.58M |
164.81M |
5.90% |
2023-06-29 |
State Street Corporation |
7.07M |
121.59M |
4.35% |
2023-06-29 |
Aisling Capital Management LP |
6.07M |
104.37M |
3.73% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
4.38M |
130.98M |
2.70% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.53M |
60.69M |
2.17% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
2.90M |
49.89M |
1.79% |
2023-08-30 |
iShares Russell 2000 ETF |
2.61M |
78.06M |
1.61% |
2023-06-29 |
Vanguard Small Cap Value Index Fund |
1.71M |
29.39M |
1.05% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.62M |
27.92M |
1.00% |